Delhi HC Bars Dr Reddy's from Selling Olymviq Over Similarity with Novo Nordisk's Ozempic Susmita Roy27 March 2026 10:16 PM ISTNew Delhi: The Delhi High Court on Wednesday directed Dr. Reddy's Laboratories to temporarily stop selling its diabetes drug marketed under the brand...
Novo Slashes Wegovy Prices Amid Lilly's Mounjaro Surge in South African Market sheeba farhat26 March 2026 11:24 PM ISTJohannesburg: Novo Nordisk is cutting South African prices of its weight-loss drug Wegovy for a second time since it launched in August, local...
USFDA Approves Higher-Dose Wegovy to Boost Weight Loss Outcomes sheeba farhat21 March 2026 11:00 AM ISTWashington: Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users lose more...
Semaglutide Patent Expiry Sparks Generic Rush in India, Prices Set to Drop Sharply sheeba farhat20 March 2026 11:13 PM ISTHyderabad: India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires...
USFDA Flags Compliance Issues at Novo Nordisk's New Jersey Facility sheeba farhat12 March 2026 10:30 AM ISTCopenhagen: Novo Nordisk said on Tuesday it had received a warning letter from the U.S. Food and Drug Administration regarding an inspection at the...
Pfizer's GLP-1 Drug Xianweiying Wins China Approval for Long-Term Weight Management sheeba farhat8 March 2026 11:30 AM ISTShanghai: China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said...
India's Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch, See Full List Farhat Nasim4 March 2026 10:15 PM ISTNew Delhi: The expiry of semaglutide's key patent in India in March 2026 is ushering in a tsunami of generic versions of the blockbuster diabetes and...
Novo Nordisk to Invest USD 506 Million to Expand Oral GLP-1 Drug Manufacturing in Ireland sheeba farhat3 March 2026 8:46 PM ISTNew Delhi: Novo Nordisk said on Monday it will invest 432 million euros (USD 506.43 million) to expand its manufacturing facility in Athlone,...
CagriSema Fails to Demonstrate Noninferiority to Tirzepatide for Weight Loss: Phase 3 REDEFINE Trial Dr. Kamal Kant Kohli24 Feb 2026 9:15 AM ISTTopline results from a phase 3 clinical trial compared CagriSema with tirzepatide in patients with obesity. CagriSema is a fixed-dose combination of...
USFDA Flags Novo Nordisk's Wegovy Advertisement as False, Seeks Immediate Action sheeba farhat11 Feb 2026 8:19 PM ISTUSFDA said the television spot misleadingly suggests that Wegovy in its pill form offers an advancement or improvement over other weight-loss drugs...
Novo Nordisk Loses USD 50 Billion as Obesity Drug Price War Triggers Profit, Sales Warning sheeba farhat6 Feb 2026 11:15 AM ISTNew Delhi: Novo Nordisk's shares tumbled on Wednesday, knocking nearly USD 50 billion in value from the Danish obesity drug giant, as it warned that...
Emcure Beats 9 Rivals to Secure Second Semaglutide Brand from Novo Nordisk for India Parthika Patel5 Feb 2026 10:31 PM ISTNew Delhi: Emcure Pharmaceuticals has secured exclusive rights to market a second brand of semaglutide in India through a partnership with Novo...
